Whitehawk Therapeutics (NASDAQ:WHWK) CEO David James Lennon Sells 26,858 Shares of Stock

Key Points

• CEO David James Lennon sold 26,858 shares on April 2 at an average price of $3.48 for about $93,466, trimming his stake by 3.27% to 793,549 shares valued at roughly $2.76 million.
• Whitehawk (NASDAQ:WHWK) was trading at $3.51 with daily volume below its average; the stock has a one‑year range of $1.39–$4.48, a market cap of about $165.7 million and a P/E of 7.47.
• Analyst coverage is mixed but the consensus is a "Hold" with an average target price of $6.50 (two Buys, one Hold, one Sell, recent targets $6.00–$7.00).

Whitehawk Therapeutics, Inc. (NASDAQ:WHWK - Get Free Report) CEO David James Lennon sold 26,858 shares of the firm's stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $3.48, for a total value of $93,465.84. Following the completion of the sale, the chief executive officer directly owned 793,549 shares of the company's stock, valued at $2,761,550.52. The trade was a 3.27% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

David James Lennon also recently made the following trade(s):

• On Monday, March 2nd, David James Lennon sold 5,100 shares of Whitehawk Therapeutics stock. The shares were sold at an average price of $3.31, for a total transaction of $16,881.00.

Whitehawk Therapeutics Stock Performance

NASDAQ WHWK remained flat at $3.51 during trading on Friday. 94,903 shares of the company's stock traded hands, compared to its average volume of 205,596. Whitehawk Therapeutics, Inc. has a 1-year low of $1.39 and a 1-year high of $4.48. The firm has a market capitalization of $165.67 million, a P/E ratio of 7.47 and a beta of 0.57. The stock has a 50 day simple moving average of $3.28 and a two-hundred day simple moving average of $2.66.

Whitehawk Therapeutics (NASDAQ:WHWK - Get Free Report) last posted its earnings results on Thursday, March 12th. The company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.21.

Institutional Investors Weigh In On Whitehawk Therapeutics

Several hedge funds have recently bought and sold shares of WHWK. Quadrature Capital Ltd purchased a new stake in Whitehawk Therapeutics in the fourth quarter worth about $28,000. ABG Innovation Capital Partners III GP Ltd bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $51,000. Dimensional Fund Advisors LP bought a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $84,000. Squarepoint Ops LLC purchased a new stake in shares of Whitehawk Therapeutics in the 3rd quarter worth approximately $159,000. Finally, Marshall Wace LLP purchased a new stake in shares of Whitehawk Therapeutics in the 4th quarter worth approximately $164,000. Institutional investors own 52.08% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on WHWK shares. Wall Street Zen upgraded Whitehawk Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, March 21st. JonesTrading started coverage on Whitehawk Therapeutics in a research note on Monday, December 22nd. They issued a "buy" rating and a $7.00 target price for the company. Oppenheimer started coverage on Whitehawk Therapeutics in a research report on Thursday, February 5th. They set an "outperform" rating and a $6.00 price target on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Whitehawk Therapeutics in a research note on Friday, March 27th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Whitehawk Therapeutics presently has a consensus rating of "Hold" and an average target price of $6.50.

About Whitehawk Therapeutics

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. The company was incorporated in 2007 and is headquartered in Pacific Palisades, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.